movement-disorders
(2)Company
Company
Health · Enterprise
Neurocrine Biosciences
One movement-disorder medicine turned a San Diego research shop into a multibillion-dollar biopharma. Now Neurocrine is spending that advantage on rare endocrine disease, psychiatry and the difficult biology between brain and body.
neurocrine-biosciences · biopharmaRead →
Health
Vima Therapeutics
Vima Therapeutics is a Cambridge, Massachusetts clinical-stage biotechnology company developing VIM0423, a potential first-in-class once-daily oral therapy for isolated dystonia and Parkinson's disease. The drug selectively targets muscarinic cholinergic receptors in the brain to correct the dopamine-acetylcholine imbalance underlying these movement disorders. Incubated at Atlas Venture and led by neurologist Bernard Ravina, the company emerged from stealth in 2025 and has raised a $100 million Series A.
biotech · neuroscienceRead →